

Special Issue

Ophthalmic Drugs and Pharmacology

Message from the Guest Editors

The field of ophthalmic pharmacology is continuing to evolve at a rapid pace, driven by advances in drug discovery, delivery technologies, and translational research. Ophthalmic diseases, including glaucoma, corneal disorders, retinal degeneration, ocular surface disease, and uveitis remain among the leading causes of visual impairment worldwide. Innovative pharmacological approaches are essential in addressing unmet needs, reducing the treatment burden, and improving patient outcomes. We invite contributions covering (but not limited to) the following topics: Novel drug development; Drug delivery systems; Repurposed therapies; Pharmacogenomics and precision medicine; Adverse drug reactions and pharmacovigilance in ophthalmic care; Health economics and patient perspectives on pharmacological treatments. We look forward to your contributions to this exciting Special Issue, which will serve as a platform to showcase innovation and impacts in the pharmacological treatment of eye diseases.

Guest Editors

Dr. Christin Henein

National Institute for Health and Care Research Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London Institute of Ophthalmology, London EC1V 2PD, UK

Dr. Sahar Awwad

National Institute for Health and Care Research Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London Institute of Ophthalmology, London EC1V 2PD, UK

Deadline for manuscript submissions

1 May 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/254126

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)